|
Status |
Public on Apr 29, 2024 |
Title |
SNU-449 ALK targeted inhibition cells (Replicate_3) |
Sample type |
SRA |
|
|
Source name |
SNU-449 cell lines
|
Organism |
Homo sapiens |
Characteristics |
genotype/variation: ALK Targeted Inhibition cells cell line: SNU-449
|
Treatment protocol |
HepG2, SK-HEP1 and SNU449 cells stably expressing either Non-Targeting or ALK targeted inhibition were used for preparing the total RNA and to perfrom gene expression array.
|
Growth protocol |
HepG2 and SK-HEP1 cells stably expressing either Non-Targeting or ALK Targeted inhibition were grown in DMEM medium with 10% Fetal bovine serum and Penicilline and Streptomycin at 37 C under 5% CO2 condition. SNU449 cells were growth in RPMI-1640 with 10% FBS plus Penicilline and Streptomycin at the same condition as the other two cell lines.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using Trizol reagent (Invitrogen) as per the instruction from the manufacture and then purified using RNAeasy mini columns (Qiagen) as per the manufactures instructions.
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 3000 |
|
|
Description |
T18
|
Data processing |
The reads were first mapped to the latest UCSC transcript set using Bowtie2 version 2.1.0 and the gene expression level was estimated using RSEM v1.2.15. Genome_build: hg38 Supplementary_files_format_and_content: tab-delimited text files include raw count values for each Sample
|
|
|
Submission date |
Jun 15, 2021 |
Last update date |
Apr 29, 2024 |
Contact name |
Narendra Wajapeyee |
E-mail(s) |
nwajapey@uab.edu
|
Phone |
205-934-5331
|
Organization name |
University of Alabama at Birmingham
|
Department |
Department of Biochemistry and Molecular Genetics
|
Street address |
720 20th Street South, Kaul 540A
|
City |
Birmingham |
State/province |
AL |
ZIP/Postal code |
35233 |
Country |
USA |
|
|
Platform ID |
GPL21290 |
Series (1) |
GSE178211 |
ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models |
|
Relations |
BioSample |
SAMN19708404 |
SRA |
SRX11146103 |